Literature DB >> 31838735

Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.

Mona Oliveira1,2, Lourenço Luis Botelho de Santana3,4, José Claudio Serafim3,4, Airam Oliveira Santos3, Michelle Pereira Quintino3,4, José Tiago Menezes Correia3, Fabiano Damasceno3, José Ricardo Sabino5, Thiago Rubens Cardim Pires1,2, Paulo Lucas Cerqueira Coelho1,2, Giselle Pinto de Faria Lopes1,6, Henning Ulrich7, Silvia Lima Costa8,9, Silvio Cunha10,11.   

Abstract

Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The antitumor activity of these alkaloid-like compounds was investigated through an initial screening performed on human glioblastoma multiform (GBM) cell lines (GL-15, U251), on murine glioma cells line (C6) and on normal glial cells. Of the compounds tested, the new pyrrolo[1,2a]azepinone, [ethyl (3-oxo-1,2-diphenyl-6,7,8,9-tetrahydro-3H-pyrrolo[1,2a]azepin-9a(5H)-yl)acetate] or (Compound-13) exhibited selective cytotoxic effects on GBM-temozolomide resistant cells. Compound-13 exerted dose-dependent cytotoxic activity by promoting arrest of cells in the G0/G1 phase of the cell cycle in the first 24 h. The apoptotic effect observed was in a time-dependent manner. Anti-migratory effect promoted by the treatment with compound-13 was also observed. Moreover, healthy mixed glial cell cultures from rat brain exhibited no cytotoxicity effect upon exposure to compound-13. Thus, the present study paves the way for the use of compound-13 as novel antitumor scaffold candidate for glioma cell therapy.

Entities:  

Keywords:  Anti-tumor agent; Azabicyclic compounds; Chemoresistance; Formal aza-cyclo additions; Glioblastoma cells

Year:  2019        PMID: 31838735     DOI: 10.1007/s10637-019-00877-2

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  18 in total

1.  Continuous changes in electroencephalographic topograms and auditory reaction time during simulated 21 ATA (atmospheres absolute) heliox saturation dives.

Authors:  K Ozawa; J Tatsuno
Journal:  Ann Physiol Anthropol       Date:  1989-10

2.  Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).

Authors:  Ahmed Elkamhawy; Ambily Nath Indu Viswanath; Ae Nim Pae; Hyeon Young Kim; Jin-Chul Heo; Woo-Kyu Park; Chong-Ock Lee; Heekyoung Yang; Kang Ho Kim; Do-Hyun Nam; Ho Jun Seol; Heeyeong Cho; Eun Joo Roh
Journal:  Eur J Med Chem       Date:  2015-08-04       Impact factor: 6.514

Review 3.  Targeting apoptosis pathways in glioblastoma.

Authors:  Günter Eisele; Michael Weller
Journal:  Cancer Lett       Date:  2011-01-26       Impact factor: 8.679

4.  Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation.

Authors:  S L Costa; E Paillaud; C Fages; C Rochette-Egly; J L Plassat; H Jouault; A Perzelova; M Tardy
Journal:  Eur J Cancer       Date:  2001-03       Impact factor: 9.162

5.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Authors:  Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

6.  The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Authors:  Barbara Banelli; Elisa Carra; Federica Barbieri; Roberto Würth; Federica Parodi; Alessandra Pattarozzi; Roberta Carosio; Alessandra Forlani; Giorgio Allemanni; Daniela Marubbi; Tullio Florio; Antonio Daga; Massimo Romani
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  Survival comparison between glioblastoma multiforme and other incurable cancers.

Authors:  B Tran; M A Rosenthal
Journal:  J Clin Neurosci       Date:  2010-02-18       Impact factor: 1.961

Review 8.  In vivo models of primary brain tumors: pitfalls and perspectives.

Authors:  Peter C Huszthy; Inderjit Daphu; Simone P Niclou; Daniel Stieber; Janice M Nigro; Per Ø Sakariassen; Hrvoje Miletic; Frits Thorsen; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2012-06-07       Impact factor: 12.300

Review 9.  Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.

Authors:  Salvador Villà; Carme Balañà; Sílvia Comas
Journal:  Chin J Cancer       Date:  2013-12-11

10.  Functional network analysis of gene-phenotype connectivity associated with temozolomide.

Authors:  Jia Shi; Bo Dong; Peng Zhou; Wei Guan; Ya Peng
Journal:  Oncotarget       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.